HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Buy rating for Voyager Therapeutics with a maintained price target of $30.
October 24, 2024 | 7:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Voyager Therapeutics, maintaining a price target of $30, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $30 price target by HC Wainwright & Co. suggests a positive outlook for Voyager Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100